Clarus preps for '13 US oral testosterone filing on back of solid data
This article was originally published in Scrip
Executive Summary
In about two years, Clarus Therapeutics' CLR-610 could be the first effective oral testosterone (T) replacement therapy on the market without the liver toxicity associated with methyltestosterone, if safety data from the first 90 days of the private Northbrook, Illinois-based company's Phase III clinical trial hold up in a longer term analysis.